Mitralign, Inc. is the valve repair company with the only direct transcatheter annuloplasty system designed to treat both functional mitral regurgitation and tricuspid regurgitation. We are a venture-backed, medical innovation company located near Boston, Massachusetts, USA.
We’ve developed an innovative therapy for the reduction of functional mitral regurgitation (FMR), a life-threatening cardiac condition affecting four million people in the U.S. alone1. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation (MR ≥ 3+) for annular reduction through tissue plication. In addition, we have developed an approach to treating tricuspid valve regurgitation with a delivery system designed for transcatheter tricuspid valve repair. Our unique system provides a new solution for interventional cardiologists and their patients.